Results 251 to 260 of about 1,111,327 (316)

Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemia. [PDF]

open access: yesSignal Transduct Target Ther
Gonzales F   +19 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Acute Leukemia

Hematology/Oncology Clinics of North America, 2014
Although great progress has been made in the understanding and treatment of acute leukemia, this disease has not been conquered. For emergency providers (EPs), the presentation of these patients to an emergency department presents a host of challenges.
Hayley, Rose-Inman, Damon, Kuehl
openaire   +3 more sources

Leukemia

2016
Leukemias are a group of life threatening malignant disorders of the blood and bone marrow. In the adolescent and young adult (AYA) population, the acute leukemias are most prevalent, with chronic myeloid leukemia being infrequently seen. Factors associated with more aggressive disease biology tend to increase in frequency with increasing age, whilst ...
Gunnar, Juliusson, Rachael, Hough
openaire   +2 more sources

Leukemia vaccines

Current Oncology Reports, 2001
Leukemia is susceptible to immune-mediated therapies such as allogeneic stem-cell transplantation, donor lymphocyte infusion, and interferon. The clinical effectiveness of these immune-based modalities has encouraged interest in vaccine therapies for leukemia.
J N, Kochenderfer, J J, Molldrem
openaire   +2 more sources

Leukemia Cutis

Dermatologic Clinics, 1994
Leukemia cutis is an uncommon manifestation of leukemia that is strongly associated with the presence of extramedullary disease at other sites. Patients usually present with leukemia cutis concomitantly with systemic leukemia or after leukemia has been diagnosed.
K V, Ratnam, C J, Khor, W P, Su
openaire   +2 more sources

Prolymphocytic leukemia

Current Treatment Options in Oncology, 2005
Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
Ahmed, Absi, Eric, Hsi, Matt, Kalaycio
openaire   +2 more sources

Home - About - Disclaimer - Privacy